2022 FDA TIDES (Peptides and Oligonucleotides) Harvest

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 Mar 29

PMID 36986436

Authors

Othman Al Musaimi

Danah Al Shaer

Fernando Albericio

Beatriz G de la Torre

Affiliations

Soon will be listed here.

Abstract

A total of 37 new drug entities were approved in 2022; although that year registered the lowest number of drug approvals since 2016, the TIDES class consolidated its presence with a total of five authorizations (four peptides and one oligonucleotide). Interestingly, 23 out of 37 drugs were first-in-class and thus received fast-track designation by the FDA in categories such as breakthrough therapy, priority review voucher, orphan drug, accelerated approval, and so on. Here, we analyze the TIDES approved in 2022 on the basis of their chemical structure, medical target, mode of action, administration route, and common adverse effects.

Citing Articles

Prediction of hemolytic peptides and their hemolytic concentration.

Rathore A, Kumar N, Choudhury S, Mehta N, Raghava G Commun Biol. 2025; 8(1):176.

PMID: 39905233 PMC: 11794569. DOI: 10.1038/s42003-025-07615-w.

Peptide-based amyloid-beta aggregation inhibitors.

Sehra N, Parmar R, Jain R RSC Med Chem. 2025; .

PMID: 39882170 PMC: 11773382. DOI: 10.1039/d4md00729h.

Full sequencing of 100mer sgRNA via tandem mass spectrometry by targeted RNase H digestion with customized probes.

Gawlig C, Hirschberger R, Hanci G, Schott S, Marandi S, Hesse I Anal Bioanal Chem. 2025; 417(8):1497-1506.

PMID: 39833501 DOI: 10.1007/s00216-025-05737-y.

Editorial: Peptides against infectious diseases: from antimicrobial peptides to vaccines.

Bojarska J, Wang X, Skwarczynski M Front Pharmacol. 2024; 15:1522148.

PMID: 39723250 PMC: 11668749. DOI: 10.3389/fphar.2024.1522148.

Development of a peptide-based tumor-activated checkpoint inhibitor for cancer immunotherapy.

Zhao Z, Fetse J, Mamani U, Guo Y, Li Y, Patel P Acta Biomater. 2024; 193:484-497.

PMID: 39716541 PMC: 11788053. DOI: 10.1016/j.actbio.2024.12.051.

References

Al Shaer D, Al Musaimi O, Albericio F, de la Torre B . 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel). 2020; 13(3). PMC: 7151716. DOI: 10.3390/ph13030040. View

Keam S . Lutetium Lu 177 Vipivotide Tetraxetan: First Approval. Mol Diagn Ther. 2022; 26(4):467-475. PMC: 9099330. DOI: 10.1007/s40291-022-00594-2. View

Mullard A . 2022 FDA approvals. Nat Rev Drug Discov. 2023; 22(2):83-88. DOI: 10.1038/d41573-023-00001-3. View

Al Shaer D, Al Musaimi O, Albericio F, de la Torre B . 2018 FDA Tides Harvest. Pharmaceuticals (Basel). 2019; 12(2). PMC: 6631726. DOI: 10.3390/ph12020052. View

Habtemariam B, Karsten V, Attarwala H, Goel V, Melch M, Clausen V . Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clin Pharmacol Ther. 2020; 109(2):372-382. DOI: 10.1002/cpt.1974. View

Hofman M, Emmett L, Sandhu S, Iravani A, Joshua A, Goh J . [Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021; 397(10276):797-804. DOI: 10.1016/S0140-6736(21)00237-3. View

Robic C, Port M, Rousseaux O, Louguet S, Fretellier N, Catoen S . Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity. Invest Radiol. 2019; 54(8):475-484. PMC: 6661244. DOI: 10.1097/RLI.0000000000000563. View

de la Torre B, Albericio F . The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2023; 28(3). PMC: 9921400. DOI: 10.3390/molecules28031038. View

Rosar F, Kochems N, Bartholoma M, Maus S, Stemler T, Linxweiler J . Renal Safety of [Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. Cancers (Basel). 2021; 13(12). PMC: 8235711. DOI: 10.3390/cancers13123095. View

10.

Hao J, Bourrinet P, Desche P . Assessment of Pharmacokinetic, Pharmacodynamic Profile, and Tolerance of Gadopiclenol, A New High Relaxivity GBCA, in Healthy Subjects and Patients With Brain Lesions (Phase I/IIa Study). Invest Radiol. 2019; 54(7):396-402. DOI: 10.1097/RLI.0000000000000556. View

11.

Keam S . Vutrisiran: First Approval. Drugs. 2022; 82(13):1419-1425. DOI: 10.1007/s40265-022-01765-5. View

12.

de la Torre B, Albericio F . The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2022; 27(3). PMC: 8839730. DOI: 10.3390/molecules27031075. View

13.

Fabrizi F, Dixit V, MARTIN P . Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006; 24(6):935-44. DOI: 10.1111/j.1365-2036.2006.03086.x. View

14.

Frias J, Davies M, Rosenstock J, Perez Manghi F, Lando L, Bergman B . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021; 385(6):503-515. DOI: 10.1056/NEJMoa2107519. View

15.

Thomas M, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K . Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2020; 106(2):388-396. PMC: 7823251. DOI: 10.1210/clinem/dgaa863. View

16.

Wahsner J, Gale E, Rodriguez-Rodriguez A, Caravan P . Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. Chem Rev. 2018; 119(2):957-1057. PMC: 6516866. DOI: 10.1021/acs.chemrev.8b00363. View

17.

Al Shaer D, Al Musaimi O, Albericio F, de la Torre B . 2021 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel). 2022; 15(2). PMC: 8876803. DOI: 10.3390/ph15020222. View

18.

Adams D, Tournev I, Taylor M, Coelho T, Plante-Bordeneuve V, Berk J . Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2022; 30(1):1-9. DOI: 10.1080/13506129.2022.2091985. View

19.

Hoy S . Patisiran: First Global Approval. Drugs. 2018; 78(15):1625-1631. DOI: 10.1007/s40265-018-0983-6. View

20.

Al Musaimi O, Al Shaer D, de la Torre B, Albericio F . 2017 FDA Peptide Harvest. Pharmaceuticals (Basel). 2018; 11(2). PMC: 6027222. DOI: 10.3390/ph11020042. View